[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:extrapulmonary-small-cell-neuroendocrine-carcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Extrapulmonary Small Cell Neuroendocrine Carcinoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06788938","Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms",[11],"Phase 2","RECRUITING","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.447902Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT02146170","Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors",[],"2026-08-26T02:18:24.494016Z","2026-05-13T02:55:06.091262Z",[],[]]